Uploaded February 2026 | Updated November 2026, 3 hours ago
Una actualización sobre terapias emergentes, estudios clínicos en curso y lo que significan para el futuro del tratamiento de trastornos neuroinmunes raros. Se explica cómo funcionan los ensayos y qué considerar antes de participar.
María Isabel Reyes Mantilla, MD | Hospital Simón Bolívar, Colombia
Una actualización sobre terapias emergentes, estudios clínicos en curso y lo que significan para el futuro del tratamiento de trastornos neuroinmunes raros. Se explica cómo funcionan los ensayos y qué considerar antes de participar.
María Isabel Reyes Mantilla, MD | Hospital Simón Bolívar, Colombia
![2026 RNDS | Family Resilience: Siblings, Mental Health, and Building Independence
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Jaclyn Aldrich, PhD, a pediatric acute care psychologist, and Camille S. Wilson, PhD, a pediatric neuropsychologist, both of Nationwide Childrens Hospital, spoke about family resilience, supporting siblings, mental health, and building independence. They described how siblings experience the first illness, the hospital stay, and recovery, and offered ways to share clear, age-appropriate information, prepare siblings for hospital visits, and keep one-on-one time and activities going [00:01:31]. They then looked at how parents roles shift across the phases of illness, including uncertainty, worry about the future, a sense of grief, and ways to restore a feeling of control and connect with other families [00:10:04]. Parents and other audience members shared their own experiences, including the gap in support between pediatric cancer and rare neuroimmune disorders, the long arc of recovery, and the value of camps [00:17:46]. The session ended with moving from pediatric to adult health care, and with resources such as the Courageous Parents Network and books for siblings [00:26:00].
Camille S. Wilson, PhD, ABPP, is a pediatric neuropsychologist at Nationwide Childrens Hospital and a clinical assistant professor of pediatrics at The Ohio State University. Her clinical work focuses on neuropsychology for children with immune-related conditions, including neuroimmune conditions such as demyelinating syndromes and autoimmune encephalitis, and on helping young people and their families prepare for the move to adulthood. She conducts clinical research in spina bifida, neuroimmune conditions and chronic kidney disease, and completed her internship and fellowship at Nationwide Childrens Hospital.
Jaclyn T. Aldrich, PhD, is an acute care psychologist at Nationwide Childrens Hospital and a clinical assistant professor at The Ohio State University. A member of the hospitals pediatric acute treatment team, she specializes in crisis intervention and treatment for young people, including suicidality and self-harm, depression and anxiety. Dr. Aldrich earned her doctorate at Seattle Pacific University, completed her internship at Primary Childrens Hospital and her fellowship at Seattle Childrens Hospital.
00:00 Welcome and Introductions
00:31 The Family Experience of Illness
01:31 How Siblings Experience Illness
05:06 Supporting Siblings
10:04 Parents and Care Partner Roles
12:40 Common Concerns for Parents
15:27 Supporting Parents
17:46 Sharing Experiences
18:59 Gaps in Support Between Conditions
23:14 Long-Term Recovery and Camps
26:00 Moving to Adult Health Care
30:19 Resources for Families 2026 RNDS | Family Resilience: Siblings, Mental Health, and Building Independence](https://i.ytimg.com/vi/_E02K_OzoQY/mqdefault.jpg)
![1308. Parenting is Hard | Part 4
At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submit
In the fourth part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA continued her conversation with Barbara Babcock. In this episode, Barbara, a family therapist, discussed her research of parental fatigue and limited time distribution among families of children who have been diagnosed with a rare neuroimmune disorder. She elaborated on the non-stop nature of caregiving roles and the impact of work and daily parenting responsibilities on parental exhaustion [00:05:10]. Barbara emphasized the importance of parents finding ways to cope, from getting social support to attending to their own basic needs [00:17:35]. She highlighted the significance of confidence in navigating the complexities of family life and caregiving for a child with special needs [00:21:27].
00:00 Introduction
01:29 Theme Two: I Can Only Split Myself So Many Ways
05:10 Parental Exhaustion and Coping Mechanisms
17:35 Balancing Social and Extracurricular Activities
21:27 Building Confidence as a Family
23:28 Conclusion
Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdoms National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at Kings College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk 1308. Parenting is Hard | Part 4](https://i.ytimg.com/vi/_FXYjc3Gpso/mqdefault.jpg)
![2024 RNDS | Advances in Immunotherapies and Tolerance
At the 2024 RNDS, Dr. Michael Yeaman of UCLA shared an overview of the advances in immunotherapy and tolerization, focusing on the progress made in the field of neuromyelitis optica spectrum disorder (NMOSD) over the past 15 years. Key points included the significant milestones in NMOSD research, the revolution in clinical care, and the emerging technologies aimed at restoring immune tolerance [00:02:03]. Dr. Yeaman discussed the unmet needs in the field, such as the risks associated with current therapies and the need for safer treatments [00:08:12]. The presentation concluded with insights into the exciting future of antigen-specific tolerance as a cure for autoimmune diseases [00:29:39]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Meeting Context
00:17 Overview of Advances in Immunotherapy & Tolerization
00:48 Disclosures and Contributions
01:07 Key Points in NMOSD Research
02:03 NMOSD Revolution and Progress
04:40 Scientific Summary of NMOSD
08:12 Unmet Needs in NMOSD Treatment
11:24 Crash Course in Immune Tolerance
18:18 Restoring Immune Tolerance
20:26 Emerging Technologies in Tolerization
25:19 Recent Advances and Clinical Trials
29:39 Conclusion and Future Outlook
31:23 Closing Remarks and Resources 2024 RNDS | Advances in Immunotherapies and Tolerance](https://i.ytimg.com/vi/_KbK56pIMhA/mqdefault.jpg)
![2026 RNDS | Latest Updates from the METEOROID Trial
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Eoin Flanagan, MD, of Mayo Clinic joined remotely to share results from the phase three METEOROID trial of satralizumab, an interleukin-6 receptor blocker, in relapsing MOG antibody disease (MOGAD) [00:00:05]. He explained how interleukin-6 signaling relates to MOG antibody production and the blood-brain barrier [00:01:02], then described the randomized, double-blind design, which enrolled 132 people age 12 and older with relapsing MOGAD [00:04:15]. Dr. Flanagan reviewed the results, including a 68% reduction in the risk of a new relapse with satralizumab compared with placebo, along with fewer new MRI lesions [00:07:59]. He closed with safety findings that were similar between the two groups and thanked the participants and investigators [00:10:58].
Eoin Flanagan, MD, is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota. He completed medical school at University College Dublin in 2005, then a neurology residency, fellowships in neuroimmunology, and a masters in clinical and translational science at Mayo Clinic. His clinical expertise and research focus on inflammatory myelopathies and their imaging patterns, MOGAD, neuromyelitis optica spectrum disorder, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH R01 grant studying MOGAD.
00:00 Welcome and Introduction
01:02 How Satralizumab Works
01:58 Why a Trial Was Needed
04:15 How the Trial Was Designed
04:49 Who Took Part
07:59 Main Results on Relapses
09:28 Other Measures and MRI Findings
10:58 Safety and Tolerability
11:51 Summary of the Trial
13:19 Thanks to Participants and Closing 2026 RNDS | Latest Updates from the METEOROID Trial](https://i.ytimg.com/vi/_O2nkwjRQXw/mqdefault.jpg)
![2024 RNDS | Care for the Caregiver
At the 2024 RNDS, Jeff Harrington and Paula Hardeman shared their personal caregiving journeys and emphasized the importance of self-care [00:01:00]. Both highlighted their initial struggles, with Jeff talking about his daughters acute disseminated encephalomyelitis (ADEM) diagnosis and Paula discussing her mothers Alzheimer’s diagnosis [00:10:37]. The session included audience questions. They underscored the need for effective communication, seeking external help, and the value of family support [00:20:42]. The discussion also featured insights from the audience, including planning for future care and the benefits of utilizing various resources [00:45:50]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction to Jeff and Paula
00:19 Jeffs Caregiving Journey
04:51 Paulas Story and Caregiving Experience
07:58 Strategies for Self-Care and Support
13:12 Resources and Community Support
16:34 Personal Stories and Emotional Insights
22:25 Balancing Caregiving and Personal Life
36:55 Planning for the Future
37:37 Facing the Reality of Caregiving
38:33 Financial and Legal Preparations
41:46 Daily Life and Advocacy
44:04 Travel Challenges and Solutions
47:15 Understanding Hospice and Palliative Care
49:49 Maintaining Relationships and Self-Care
51:52 Practical Tips for Caregivers
01:00:39 The Importance of Advocacy and Communication
01:05:22 Final Thoughts and Reflections 2024 RNDS | Care for the Caregiver](https://i.ytimg.com/vi/_Q8398Ii_jE/mqdefault.jpg)
![1212. The Role of Physicians and Patients in Legislative Advocacy
In this episode of Ask the Expert, hosted by Krissy Dilger of SRNA, Dr. Shuvro Roy talked about the importance of legislative advocacy in healthcare [00:01:10]. Dr. Roy discussed how physicians can engage in legislative advocacy by sharing their practice stories and providing technical expertise [00:05:05]. He emphasized the crucial role of patients in advocacy, highlighting that their personal stories carry significant weight with legislators [00:07:45]. Dr. Roy also shared examples of successful advocacy efforts, such as telemedicine policy changes and Medicare reforms, contributing to better patient outcomes [00:15:10].
Shuvro Roy, MD is an assistant professor of Neurology at the University of Washington, specializing in Neuroimmunology. He completed his neuroimmunology and neuroinfectious disease fellowship at Johns Hopkins University. He graduated from Medical School at Ohio State University and completed his neurology residency at University of California, Los Angeles. Dr. Roy is actively engaged with a number of projects to improve access to care, healthcare inequality, and patient safety for people with MS and related conditions, with a special interest in neuromyelitis optica and MOG antibody disease. His primary research focus examines how to better leverage health systems to understand and treat neuroimmunologic disorders. He chose to work with people who have MS and rare neuroimmunologic conditions because of the opportunity to build longstanding patient-provider relationships and to help his patients thrive in the face of challenging lifelong conditions.
00:00 Introduction to the Podcast
00:36 Meet Dr. Roy: Our Expert Guest
01:05 Importance of Legislative Advocacy in Healthcare
02:54 Physicians Role in Legislative Advocacy
06:13 Patients Role in Legislative Advocacy
07:51 Examples of Successful Advocacy Efforts
11:52 Current Legislative Issues Impacting the Community
15:28 Effective Communication with Legislators
18:15 Barriers to Advocacy
20:34 The Role of Medical Research in Advocacy
23:47 Collaborating with Stakeholders
27:58 Advice for New Advocates
31:37 Conclusion and Final Thoughts 1212. The Role of Physicians and Patients in Legislative Advocacy](https://i.ytimg.com/vi/_V8IKqkS8y8/mqdefault.jpg)
![2026 RNDS | Welcome Remarks and Conference Orientation
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern and Carlos A. Pardo, MD, of Johns Hopkins University welcomed attendees to Texas and thanked SRNA staff and the symposium sponsors [00:00:05]. Dr. Greenberg ran a live Slido poll asking for one word that describes what people hope to gain from RNDS, and knowledge, hope, education, connection and community rose to the top [00:01:31]. The two reflected on why the symposium has stayed in person for 27 years, and Dr. Greenberg previewed the afternoon: a community panel on diagnosis, a diagnostic workup discussion, and two talks on new diagnostic criteria [00:04:25]. Dr. Pardo recalled how the Transverse Myelitis Association began in the 1990s, how the Johns Hopkins transverse myelitis center and patient registry started in 1999, and how antibody discoveries changed care for neuromyelitis optica and MOG antibody disease (MOGAD) [00:09:10]. He closed by describing what the weekend would cover, from diagnosis updates to long-term management [00:13:18].
Benjamin Greenberg, MD, MHS, received his bachelors degree from Johns Hopkins University and his masters degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health. He attended medical school at Baylor College of Medicine and completed his neurology residency at The Johns Hopkins Hospital, where he later became Co-Director of the Transverse Myelitis Center. In 2009 he was recruited to the University of Texas Southwestern Medical Center, where he directs the Transverse Myelitis and Neuromyelitis Optica Program and established the Pediatric Demyelinating Disease Program at Childrens Medical Center Dallas. He is recognized internationally as an expert in rare autoimmune disorders of the central nervous system, including transverse myelitis, neuromyelitis optica spectrum disorder, ADEM and autoimmune encephalitis.
Carlos A. Pardo, MD, is a Professor of Neurology and Pathology in the Division of Neuroimmunology and Neuroinfectious Disorders at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Myelitis and Myelopathy Center in Baltimore, Maryland. He is the principal investigator of the Neuroimmunopathology Laboratory and a clinical neurologist at the Multiple Sclerosis and Transverse Myelitis Centers at Johns Hopkins Hospital. His clinical specialization is neuroimmunological and infectious disorders of the nervous system, with particular focus on multiple sclerosis, transverse myelitis, neurosarcoidosis, and neurological complications of autoimmune disorders.
00:00 Welcome to Texas and Thank You
01:31 Slido Poll: Hopes for RNDS
03:38 Words for the SRNA Community
04:25 Why We Meet in Person
06:25 What to Expect Today
09:10 Dr. Pardos Welcome
10:22 Starting the Myelitis Center at Johns Hopkins
12:13 Twenty-Five Years of Progress
13:18 Looking Ahead to the Weekend 2026 RNDS | Welcome Remarks and Conference Orientation](https://i.ytimg.com/vi/_XFsMC3-jXs/mqdefault.jpg)
![2024 RNDS | Plasma Exchange for Acute Inflammatory Demyelination: How We Got Here and Where to Next?
At the 2024 RNDS, Dr. Ben Greenberg provided context on the history and evolution of the Siegel Rare Neuroimmune Association (SRNA) celebrating its 30th anniversary, with a special mention of Brian Weinshenkers pioneering work on plasmapheresis 25 years ago [00:00:47]. Dr. Brian Weinshenker then shared the results and impact of his research on plasma exchange for treating acute demyelinating diseases, including a significant study from the late 1990s [00:07:26]. He discussed the challenges of implementing this treatment and compares it with other approaches, emphasizing the need for further research and careful trial design [00:14:03]. The video concluded with insights into future directions and emerging treatments to enhance the management of these diseases [00:20:30]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Context
00:39 Personal Story: Early Days of Plasmapheresis
02:45 Brian Weinshenkers Introduction
04:04 Historical Background and Early Research
07:26 Breakthroughs in Plasma Exchange
14:04 Clinical Trials and Results
19:45 Media Coverage and Public Reaction
24:20 Comparative Studies and Ongoing Research
32:00 Future Directions and Conclusion 2024 RNDS | Plasma Exchange for Acute Inflammatory Demyelination: How We Got Here and Where to Next?](https://i.ytimg.com/vi/_uhlkK_8xvA/mqdefault.jpg)
![2026 RNDS | CAR-T Trials for NMOSD
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, spoke about CAR-T cell therapy and the trials planned for neuromyelitis optica spectrum disorder (NMOSD) [00:00:05]. He traced CAR-T from early work on HIV to cancer treatment, and explained how T cells are re-engineered, using either a persons own cells (autologous) or cells from a healthy donor (allogeneic) [00:00:42]. He described the first autologous trial for aquaporin-4 antibody-positive NMOSD, why NMOSD was chosen, and what taking part involves [00:05:26]. Dr. Levy discussed safety concerns and the 15 years of follow-up the FDA requires [00:08:13]. He compared the two donor-cell trials, which include people who are aquaporin-4 negative, MOG antibody positive or living with autoimmune encephalitis, and explained that the trials have not yet launched [00:09:15].
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
00:00 Introduction
00:14 A New Kind of Therapy
00:42 Where CAR-T Came From
01:46 What CAR-T Does
03:17 Comparison with Bone Marrow Transplant
05:26 Why NMOSD Was Chosen
06:40 Trial Design and What to Expect
08:13 Safety Concerns
09:15 Donor Cells (Allogeneic)
12:15 A Basket Study
14:26 A Second Donor-Cell Trial
18:02 Choosing Between Trials
18:44 Where the Trials Stand 2026 RNDS | CAR-T Trials for NMOSD](https://i.ytimg.com/vi/a1wfk-FpaZc/mqdefault.jpg)
![2024 RNDS | Rare Neuroimmune Disorders: Diagnostic Criteria
At the 2024 RNDS, Dr. Shruti Mahale, a 4th year medical student at UT Southwestern, presented a project on patients with rare neuroimmune disorders and emphasized the challenges in diagnosing these conditions due to overlapping symptoms with other neuroimmune diseases [00:03:12]. The study involved a questionnaire to assess patients understanding of their condition, revealing that individuals with idiopathic conditions scored lower on knowledge tests compared to those with better-characterized diseases [00:10:45]. It was noted that high health literacy and educational levels among respondents might not represent the broader population, suggesting the need for targeted educational resources [00:12:24]. The discussion with Dr. Kyle Blackburn also covered the evolution of diagnostic criteria for conditions like multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and MOG antibody disease (MOGAD), stressing the importance of regular updates to improve early diagnosis and treatment [00:14:07]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Blackburn.pdf
00:00 Introduction and Speaker Background
00:28 Overview of Rare Neuroimmune Disorders
01:41 Challenges in Diagnosing Neuroimmune Disorders
03:20 Study on Patient Understanding of Their Condition
03:30 Study Methodology and Demographics
04:54 Study Results and Conclusions
07:23 Importance of Diagnostic Criteria
09:11 Evolution of Multiple Sclerosis Criteria
10:46 Historical Perspective on Neuromyelitis Optica
14:07 Discovery and Impact of Aquaporin-4 Antibody
16:51 MOG Antibody Disease: A New Entity
21:31 Acute Flaccid Myelitis and Need for Updated Criteria
23:37 Conclusion and Final Thoughts 2024 RNDS | Rare Neuroimmune Disorders: Diagnostic Criteria](https://i.ytimg.com/vi/aS-Wr3eZSiw/mqdefault.jpg)
![2024 RNDS | Management of Visual Symptoms
At the 2024 RNDS, Dr. Peter Sguigna and Dr. Kory S. Cummings discussed the prevalence of visual symptoms in various rare neuroimmune disorders [00:01:20]. Emphasis was given to the pathophysiology and recovery phases of optic neuritis, detailing inflammation and the roles of remyelination and neuroplasticity [00:10:22]. Dr. Cummings explained her approach to patient care, particularly in the context of low vision, stressing the importance of personalized strategies [00:14:03]. The session concluded with questions from the audience about segment addressing photopsia, managing blindness with technology, and mobility aids for partial vision loss [00:29:39]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Sguigna.pdf
00:00 Introduction and Personal Story
02:23 Understanding Visual Symptoms
04:55 Optic Neuritis: Causes and Recovery
06:56 Case Studies and Diagnostic Challenges
09:18 Management of Visual Symptoms
14:03 Low Vision Specialist Insights
18:55 Chronic Phase and Pain Management
27:19 Assistive Technologies and Resources
29:39 Audience Q&A 2024 RNDS | Management of Visual Symptoms](https://i.ytimg.com/vi/aVFN7miJHlI/mqdefault.jpg)